Hypercholesterolemia
Stories
-
AstraZeneca registers Phase III trial of FDC laroprovstat/rosuvastatin in hypercholesterolemia
The study plans to enroll 204 participants and is expected to start on December 21, 2026. It aims to evaluate the effect on LDL-C and the safety and tolerability of the fixed-dose combination in lipid-lowering treatment-naïve patients.